NCT01239043已完成2 期
Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® Vaccine Approximately Three Years Following Initial Vaccination in Adults Who Participated in Trial MTA29
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Sanofi
- 入组人数
- 139
- 试验地点
- 6
- 主要终点
- Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Either Menomune or Menactra Vaccine
研究概览
简要总结
The purpose of this trial is to describe antibody persistence and response to re-vaccination with either Menactra® or Menomune® vaccine approximately three years following initial vaccination in adults who participated in trial MTA29 (NCT00874549).
Objectives:
- To describe the rates of immediate reactions, solicited injection-site and systemic reactions, all unsolicited adverse events, and serious adverse events following vaccination.
- To evaluate persistence of serum bactericidal antibodies in subjects who received Menactra® or Menomune® vaccine approximately three years ago.
- To evaluate the immune response to serogroups A, C, Y, and W-135 in subjects re-vaccinated with either Menactra® or Menomune® vaccine.
详细描述
Participants who were randomized and received either Menactra® or Menomune® vaccine in trial MTA29 will receive 1 dose of either Menactra® or Menomune®, respectively on Day 0 and will be followed-up for 28 days post-vaccination.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 56 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Aged 56 years or older on the day of inclusion.
- •Received the appropriate Menactra or Menomune vaccine as assigned by randomization in Trial MTA
- •Ambulatory and healthy, as determined by medical history.
- •Informed consent form has been signed and dated.
- •Able to attend all scheduled visits and to comply with all trial procedures.
- •For a woman of childbearing potential, use of an effective method of contraception or abstinence from at least 4 weeks prior to vaccination until at least 4 weeks after vaccination.
排除标准
- •Any condition which, in the opinion of the Investigator, would pose a health risk to the participant or interfere with the evaluation of the vaccine.
- •Known pregnancy, or a positive pregnancy test.
- •Currently breastfeeding a child.
- •History of documented invasive meningococcal disease.
- •Participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the trial vaccination.
- •Planned participation in another clinical trial during the present trial period.
- •Receipt of any meningococcal vaccine since participation in trial MTA
- •Receipt of any vaccine in the 4 weeks preceding the trial vaccination, except for influenza vaccination, which may be received at least two weeks before trial vaccination.
- •Planned receipt of any vaccine in the 4 weeks following the trial vaccination.
- •Receipt of blood or blood-derived products in the past 3 months, which might interfere with assessment of the immune response.
- •Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).
- •Laboratory-confirmed seropositivity for Human Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis C.
- •Previous personal history of Guillain-Barré Syndrome (GBS).
- •Known systemic hypersensitivity to any of the vaccine components, latex, or history of a life-threatening reaction to the vaccines used in the trial or to a vaccine containing any of the same substances.
- •Laboratory-confirmed thrombocytopenia, contraindicating intramuscular (IM) vaccination.
- •Bleeding disorder or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM vaccination.
- •Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily.
- •Current alcohol or drug use that, in the opinion of the Investigator, might interfere with the ability to comply with trial procedures.
- •Not available for the entire study period or unable to attend the scheduled visits or to comply with the study procedures.
- •Chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere with trial conduct or completion.
- •Identified as employees of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, as well as family members (i.e., immediate, husband, wife and their children, adopted or natural) of the employees or the Investigator.
结局指标
主要结局
Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Either Menomune or Menactra Vaccine
时间窗: Day 0 to Day 7 post-vaccination
Solicited Injection Site Reactions: Pain, Erythema, Swelling. Solicited Systemic Reactions: Fever (Temperature), Headache, Malaise, Myalgia. Grade 3 reactions were defined as: Pain, headache, malaise, and myalgia - significant, prevents daily activity; Erythema and swelling - \> 100 mm; Fever, temperature of ≥ 39.0ºC or ≥ 102.1ºF.
次要结局
未报告次要终点
研究者
研究点 (6)
Loading locations...
相似试验
已完成
3 期
Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentinean InfantsPoliomyelitisHepatitis BDiphtheriaTetanusPertussisNCT00303316Sanofi458
已完成
不适用
Evaluation of the Long-term Persistence of GlaxoSmithKline (GSK) Biologicals' Candidate Cytomegalovirus (CMV) VaccineInfections, CytomegalovirusNCT01357915GlaxoSmithKline47
已完成
不适用
Understanding Immunity Persistence After Adolescent MenC VaccinationAntibody Persistance After Booster Dose of Men C VaccineNCT01459432University of Oxford134
已完成
3 期
Immunological Persistence After Priming With GSK1024850A Vaccine and Safety& Immunogenicity After Booster DoseInfections, StreptococcalNCT01119625GlaxoSmithKline238
已完成
2 期
Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT and Hib-MenC-TT or Meningitec™ in Healthy ToddlersInfections, MeningococcalNCT00135564GlaxoSmithKline500